Key result
Pre-hospital high bolus dose tirofiban reduces 30-day major cardiovascular events by ~33% vs control in STEMI.
Why the study?
Does early, pre-hospital initiation of high bolus dose tirofiban reduce major adverse cardiac events in patients with STEMI undergoing primary PCI?
RCT (n=1,398)
Open-label and double-blind phases
Randomized
Does early, pre-hospital initiation of high bolus dose tirofiban reduce major adverse cardiac events in patients with STEMI undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We have received substantial feedback from physicians that there is a need for more potent antiplatelet therapy when treating STEMI patients undergoing percutaneous coronary intervention. We believe the STEMI indication would increase the utility of AGGRASTAT for physicians, and thereby increase hospital adoption and demand.”
“We are evaluating the FDA's response and will work closely with the Agency to address their comments. In the meantime, AGGRASTAT continues to be the fastest growing GPI in the United States.”
Early pre-hospital administration of high bolus dose tirofiban, added to standard therapy, reduces 30-day major adverse cardiac events in STEMI patients undergoing primary PCI.
OBJECTIVES: The purpose of this trial was to study the effect of a high bolus dose (HBD) of tirofiban on clinical outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). BACKGROUND: The On-TIME 2 (Ongoing Tirofiban In Myocardial infarction Evaluation 2) placebo-controlled, double-blind, randomized trial showed that early administration of HBD tirofiban in the ambulance improves ST-segment resolution in patients with STEMI undergoing primary percutaneous coronary intervention. The effect of early tirofiban treatment on clinical outcome is unclear. METHODS: The On-TIME 2 trial consisted of 2 phases: an open-label phase, followed by a double-blind, placebo-controlled phase. STEMI patients were randomized to either HBD tirofiban or no tirofiban (phase 1) or placebo (phase 2) in addition to aspirin, heparin, and high-dose clopidogrel. The protocol pre-specified a pooled analysis of the 2 study phases to assess the incidence of major adverse cardiac events at the 30-day follow-up and on total mortality at the 1-year follow-up. RESULTS: During a 3-year period, 1,398 patients were randomized, 414 in phase 1 and 984 in phase 2. Major adverse cardiac events at 30 days were significantly reduced (5.8% vs. 8.6%, p = 0.043). There was a strong trend toward a decrease in mortality (2.2% vs. 4.1%, p = 0.051) in patients who were randomized to tirofiban pre-treatment, which was maintained during the 1-year follow-up (3.7% vs. 5.8%, p = 0.08). No clinically relevant difference in bleeding was observed. CONCLUSIONS: Early, pre-hospital initiation of HBD tirofiban, in addition to high-dose clopidogrel, improves the clinical outcome after primary percutaneous coronary intervention in patients with STEMI. (Ongoing 2b/3a inhibition In Myocardial infarction Evaluation; ISRCTN06195297).
No takes yet. Share an insight, caveat, or question.
Berg et al. (2010) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=1,398). High bolus dose tirofiban vs. No tirofiban or placebo was evaluated on Major adverse cardiac events at 30 days (p=0.043). Early, pre-hospital initiation of high bolus dose tirofiban reduced major adverse cardiac events at 30 days compared to control in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: